JBJoel Berends

Joel Berends

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Joel Berends has a total of 128 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Abstract 1340: Nuclear biomolecular condensates regulate transcriptional responses during stress

    by Sethu Pitchiaya, Joel Berends, Vijaya Dommeti, Jeffrey Dudley, Giovana Veronezi, Srinivas Ramachandran

  • Focal Therapy Is a Viable Treatment for Low-Risk Prostate Cancer

    by Joel Berends, Ajith Dupati, John Dibianco, Arvin K. George

    Focal therapy has been introduced as a novel treatment option for clinically localized prostate cancer. However, defining its role in the clinical space is still debated, especially with regards to identifying eligible candidates who will stand to benefit from treatment. Active surveillance (AS) is established as the preferred treatment for low-risk prostate cancer, with the goal of identifying those experiencing risk re-classification for curative intervention if it occurs. AS has been shown to be inferior to whole-gland treatments in to preventing progression or metastases. As a result, the field has sought solutions outside of the dichotomous options currently presented to men with low-risk cancer. Finally, the acceptance of preservation of sexual/urinary function and the avoidance of definitive therapy as valid endpoints has forced providers to think outside of survival alone as meaningful measures of success. It is here that focal therapy has emerged as a prospective replacement to AS or definitive treatment in carefully selected men. Combined with available risk stratification tools, focal ablation may afford patients durable oncological benefit while maintaining quality of life even in low-risk cancers.


  • Lymphopenia during radiotherapy in patients with oropharyngeal cancer

    by Sweet Ping Ng, Houda Bahig, Amit Jethanandani, Courtney Pollard, Joel Berends, Erich M. Sturgis, Faye M. Johnson, Baher Elgohari, Hesham Elhalawani, David I. Rosenthal, et al.


  • Open Access

    Risk of second primary malignancies in head and neck cancer patients treated with definitive radiotherapy

    by Sweet Ping Ng, Courtney Pollard, Mona Kamal, Zeina Ayoub, Adam S. Garden, Houda Bahig, G. Brandon Gunn, Steven J. Frank, Heath D. Skinner, Jack Phan, et al.

    Second primary malignancy (SPM) may occur after index head and neck cancer (HNC) treatment. This study evaluated the prevalence and outcome of SPM in patients with HNC treated with definitive radiotherapy. Eligible patients include those with index mucosal HNC treated with definitive radiotherapy between 2000 and 2010. SPM was defined as an invasive cancer at a noncontiguous site diagnosed at least 6 months after completion of radiotherapy. Clinical data were collected, and the Kaplan–Meier method was used to estimate overall survival. In total, 1512 patients were studied. The majority of patients had index oropharyngeal cancer (86%). In all, 130 (9%) patients developed a SPM. The risk of SPM increased exponentially with time with 5-, 10-, and 15-year rates of 4, 10, and 25%. Half of SPMs were within the head and neck or thoracic regions. SPM rates were significantly higher (p < 0.0001) in current smokers and former smokers than never smokers with 5-, 10-, and 15-year risk being: never smoker (2, 4, 14%), former smokers with <10-pack year (5, 10, 23%), former smokers with ≥10-pack year (5, 14, 35%), and current smokers (6, 18, 32%). In total, 102 (78%) had subsequent curative-intent therapy. The 5-year overall survival from SPM was 44%. The majority of SPMs were in those with significant smoking history reflecting the same risk factor as for the index mucosal HNC. Nearly one in two patients with SPMs were salvaged underscoring the importance of regular surveillance for SPMs.


  • Robust response to nivolumab in patient with renal cell carcinoma inferior vena cava tumour thrombus

    by Joel Berends, Eric Gourley, Dharam Kaushik

    A 47-year-old previously healthy man presented with acute moderate flank pain. Evaluation revealed left renal cell carcinoma, with inferior vena cava tumour thrombus invasion. Patient had no significant history or risk factors to pre-dispose him to genitourinary cancers. Surgery was deemed to not be appropriate due to distant metastases, but patient received targeted molecular therapy and immunotherapy with striking regression of the thrombus.


  • Fatigue following radiation therapy in nasopharyngeal cancer survivors: A dosimetric analysis incorporating patient report and observer rating

    by Mona Kamal, David I. Rosenthal, Aakash Batra, Stefania Volpe, Baher Elgohari, Ryan P. Goepfert, Adam S. Garden, Jack Phan, Salman Eraj, Amy Dursteler, et al.


  • Usefulness of surveillance imaging in patients with head and neck cancer who are treated with definitive radiotherapy

    by Sweet Ping Ng, Courtney Pollard, Joel Berends, Zeina Ayoub, Mona Kamal, Adam S. Garden, Houda Bahig, Scott B. Cantor, Andrew J. Schaefer, Temitayo Ajayi, et al.

    Background: The current study was performed to assess the efficacy of surveillance imaging in patients with head and neck cancer (HNC) who are treated definitively with radiotherapy. Methods: Eligible patients included those with a demonstrable disease‐free interval (≥1 follow‐up imaging procedure without evidence of disease and a subsequent visit/imaging procedure) who underwent treatment of HNC from 2000 through 2010. Results: A total of 1508 patients were included. The median overall survival was 99 months, with a median imaging follow‐up period of 59 months. Of the 1508 patients, 190 patients (12.6%) experienced disease recurrence (107 patients had locoregional and 83 had distant disease recurrence). A total of 119 patients (62.6%) in the group with disease recurrence were symptomatic and/or had an adverse clinical finding associated with the recurrence. Approximately 80% of patients with locoregional disease recurrences presented with a clinical finding, whereas 60% of distant disease recurrences were detected by imaging in asymptomatic patients. Despite the earlier detection of disease recurrence via imaging, those patients in the group of patients with clinically detected disease recurrence were significantly more likely to undergo salvage therapy compared with those whose recurrence was detected on imaging (odds ratio, 0.35). There was no difference in overall survival noted between those patients with disease recurrences that were detected clinically or with imaging alone. Approximately 70% of disease recurrences occurred within the first 2 years. In those patients who developed disease recurrence after 2 years, the median time to recurrence was 51 months. After 2 years, the average number of imaging procedures per patient for the detection of a salvageable recurrence for the imaging‐detected group was 1539. Conclusions: Surveillance imaging in asymptomatic patients with HNC who are treated definitively with radiotherapy without clinically suspicious findings beyond 2 years has a low yield and a high cost. Physicians ordering these studies must use judicious consideration and discretion.


  • Open Access

    Machine Learning Applications in Head and Neck Radiation Oncology: Lessons From Open-Source Radiomics Challenges

    by Hesham Elhalawani, Timothy A Lin, Stefania Volpe, Abdallah S R Mohamed, Aubrey L White, James Zafereo, Andrew J Wong, Joel E Berends, Shady AboHashem, Bowman Williams, et al.

    Radiomics leverages existing image datasets to provide non-visible data extraction via image post-processing, with the aim of identifying prognostic, and predictive imaging features at a sub-region of interest level. However, the application of radiomics is hampered by several challenges such as lack of image acquisition/analysis method standardization, impeding generalizability. As of yet, radiomics remains intriguing, but not clinically validated. We aimed to test the feasibility of a non-custom-constructed platform for disseminating existing large, standardized databases across institutions for promoting radiomics studies. Hence, University of Texas MD Anderson Cancer Center organized two public radiomics challenges in head and neck radiation oncology domain. This was done in conjunction with MICCAI 2016 satellite symposium using Kaggle-in-Class, a machine-learning and predictive analytics platform. We drew on clinical data matched to radiomics data derived from diagnostic contrast-enhanced computed tomography (CECT) images in a dataset of 315 patients with oropharyngeal cancer. Contestants were tasked to develop models for (i) classifying patients according to their human papillomavirus status, or (ii) predicting local tumor recurrence, following radiotherapy. Data were split into training, and test sets. Seventeen teams from various professional domains participated in one or both of the challenges. This review paper was based on the contestants' feedback; provided by 8 contestants only (47%). Six contestants (75%) incorporated extracted radiomics features into their predictive model building, either alone (n = 5; 62.5%), as was the case with the winner of the “HPV” challenge, or in conjunction with matched clinical attributes (n = 2; 25%). Only 23% of contestants, notably, including the winner of the “local recurrence” challenge, built their model relying solely on clinical data. In addition to the value of the integration of machine learning into clinical decision-making, our experience sheds light on challenges in sharing and directing existing datasets toward clinical applications of radiomics, including hyper-dimensionality of the clinical/imaging data attributes. Our experience may help guide researchers to create a framework for sharing and reuse of already published data that we believe will ultimately accelerate the pace of clinical applications of radiomics; both in challenge or clinical settings.


  • Open Access

    Investigation of radiomic signatures for local recurrence using primary tumor texture analysis in oropharyngeal head and neck cancer patients

    by M. D. Anderson Cancer Center Head and Neck Quantitative Imaging Working Group, Hesham Elhalawani, Aasheesh Kanwar, Abdallah S. R. Mohamed, Aubrey White, James Zafereo, Andrew Wong, Joel Berends, Shady Abohashem, Bowman Williams, et al.

    Radiomics is one such “big data” approach that applies advanced image refining/data characterization algorithms to generate imaging features that can quantitatively classify tumor phenotypes in a non-invasive manner. We hypothesize that certain textural features of oropharyngeal cancer (OPC) primary tumors will have statistically significant correlations to patient outcomes such as local control. Patients from an IRB-approved database dispositioned to (chemo)radiotherapy for locally advanced OPC were included in this retrospective series. Pretreatment contrast CT scans were extracted and radiomics-based analysis of gross tumor volume of the primary disease (GTVp) were performed using imaging biomarker explorer (IBEX) software that runs in Matlab platform. Data set was randomly divided into a training dataset and test and tuning holdback dataset. Machine learning methods were applied to yield a radiomic signature consisting of features with minimal overlap and maximum prognostic significance. The radiomic signature was adapted to discriminate patients, in concordance with other key clinical prognosticators. 465 patients were available for analysis. A signature composed of 2 radiomic features from pre-therapy imaging was derived, based on the Intensity Direct and Neighbor Intensity Difference methods. Analysis of resultant groupings showed robust discrimination of recurrence probability and Kaplan-Meier-estimated local control rate (LCR) differences between “favorable” and “unfavorable” clusters were noted.


  • Patient reported dry mouth: Instrument comparison and model performance for correlation with quality of life in head and neck cancer survivors

    by Mona Kamal, David I. Rosenthal, Stefania Volpe, Ryan P. Goepfert, Adam S. Garden, Katherine A. Hutcheson, Karine A. Al Feghali, Mohamed Ahmed Mohamed Meheissen, Salman A. Eraj, Amy E. Dursteler, et al.